Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
World leaders, rights groups react to COP30 climate deal- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Meet Beef the bulldog, who takes slow walks with his 78-year-old friend
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- 6 Well known Ladies' Fragrances On the planet
- Nature's Best: A Manual for Beautiful Train Rides
- Former United Launch Alliance CEO Tory Bruno joins competitor Blue Origin for national security projects
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- Extreme Manual for Purchasing Your Next Truck
